1. Localisation of an occult thyrotropinoma with 11C-methionine PET-CT before and after somatostatin analogue therapy 
Olympia Koulouri, MRCP, Andrew C Hoole, PhD, Patrick English, MD, Kieren Allinson, FRCPath, Nagui Antoun, FRCR, Heok Cheow, FRCR, Prof Neil G Burnet, MD, Neil Donnelly, FRCS, Richard J Mannion, PhD, Dr Mark Gurnell, PhD 
The Lancet Diabetes & Endocrinology 
Volume 4, Issue 12, (December 2016)
DOI: /S (16)
Copyright © 2016 Elsevier Ltd Terms and Conditions

2. Figure Imaging and histopathological findings
(A) Spin echo MRI of the pituitary (top panel) and 11C-methionine PET-CT co-registered with spoiled gradient recalled acquisition MRI (bottom panel), at presentation. Repeat imaging during (B) and after (C) discontinuation of somatostatin analogue therapy. (D) Microscopic appearance (top panel) and positive thyroid-stimulating hormone immunohistochemistry (bottom panel) of resected adenoma; each scale bar represents 200 μm.
The Lancet Diabetes & Endocrinology 2016 4, DOI: ( /S (16) )
Copyright © 2016 Elsevier Ltd Terms and Conditions